Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is projected to have a promising future due to its two TYK2 inhibitors, envudeucitinib and A-005, which have shown potential in treating psoriasis, systemic lupus erythematosus (SLE), and other neurodegenerative diseases. The company's valuation, based on a sum-of-the-parts net-present-value analysis, is estimated at $17/share for Envudeucitinib in PsO and $0/share for its anticipated YE27 net cash position. While current regulatory uncertainty surrounding SLE may have led to a downgrade to NEUTRAL, Alumis remains on track to file an NDA for envudeucitinib in psoriasis in 4Q26, with potential peak sales of $139.4 million by 2035. Further updates on the TYK2 franchise, including evaluation of additional indications such as multiple sclerosis, are expected in 2Q26.

Alumis is a clinical-stage biopharmaceutical company with a focus on developing a TYK2 inhibitor, envudeucitinib, for the treatment of psoriasis and a central nervous system (CNS) penetrant allosteric TYK2 inhibitor, A-005, for a broad range of neuroinflammatory and neurodegenerative diseases. However, the company faces several downside risks including failure of phase I study of A-005, negative readthrough from other oral TYK2i programs, R&D and regulatory setbacks, potential emergence of new competitors, and the risk of needing to raise money until they become cash flow positive. Additionally, the company has a highly elevated placebo response and may face commercialization risks due to competition from established biologics in the market. The company's valuation and risks indicate a negative outlook, with potential downward revisions to projections and price target if clinical trials do not achieve targets on endpoints or if products do not obtain regulatory approval. Therefore, based on these fundamental reasons, the third person's analysis suggests a negative outlook on Alumis's stock.